2023
Effects of novel Coronavirus (COVID-19) on presentation, management, and outcomes of acute cholecystitis at an academic tertiary care center cholecystitis management during COVID-19
Peters N, O'Connor R, Bhattacharya B, Kunstman J. Effects of novel Coronavirus (COVID-19) on presentation, management, and outcomes of acute cholecystitis at an academic tertiary care center cholecystitis management during COVID-19. Heliyon 2023, 9: e22043. PMID: 38027854, PMCID: PMC10658381, DOI: 10.1016/j.heliyon.2023.e22043.Peer-Reviewed Original ResearchTertiary care centerAcute cholecystitisCare centerPersonal protective equipment (PPE) guidelinesAcademic tertiary care centerAcute surgical problemsNon-operative managementPre-operative testingCOVID-19 pandemicNon-significant trendCholecystitis patientsComplication rateStudy cohortOperative managementControl cohortCOVID cohortSurgical problemsRetrospective analysisSurgical carePatientsControl groupEquipment guidelinesCholecystitisAspects of healthcareCohortImpact of COVID-19 on the gastrointestinal surgical oncology patient population
Bakkila B, Marks V, Kerekes D, Kunstman J, Salem R, Billingsley K, Ahuja N, Laurans M, Olino K, Khan S. Impact of COVID-19 on the gastrointestinal surgical oncology patient population. Heliyon 2023, 9: e18459. PMID: 37534012, PMCID: PMC10391949, DOI: 10.1016/j.heliyon.2023.e18459.Peer-Reviewed Original ResearchGI cancer surgeryPreoperative chemotherapyCancer surgerySurgical careCOVID-19 pandemicCOVID-19Tertiary referral centerOncology patient populationFirst COVID-19 waveGI cancer casesCOVID-19 burdenHigh COVID-19 burdenEmergency surgeryReferral centerCOVID-19 waveOncology visitsGastrointestinal cancerGI cancersPatient populationStudy criteriaCancer careTreatment characteristicsCancer casesCase volumePatientsSurgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States
Kerekes D, Frey A, Bakkila B, Kunstman J, Khan S. Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States. Journal Of Surgical Oncology 2023, 128: 790-802. PMID: 37435780, DOI: 10.1002/jso.27392.Peer-Reviewed Original ResearchConceptsGastroenteropancreatic neuroendocrine carcinomasGEP-NECSingle-site surgeryOverall survivalSurgical treatmentNeuroendocrine carcinomaMortality reductionSite surgeryPrimary siteNational Cancer DatabaseRetrospective cohort studyPrimary tumor typeSurgical resectionCohort studyAggressive diseaseSurgical interventionSurvival outcomesTreatment optionsCancer DatabaseSurgeryPatientsTumor typesNECStrongest predictorCarcinoma
2020
S0101 Clinical and Demographic Predictors of Rapidly Progressive Disease in Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma: Risk Profiling From the National Cancer Database
Ilagan-Ying Y, Ying L, Ferrucci L, Peters N, Blackburn H, Kunstman J, Ahuja N. S0101 Clinical and Demographic Predictors of Rapidly Progressive Disease in Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma: Risk Profiling From the National Cancer Database. The American Journal Of Gastroenterology 2020, 115: s48-s49. DOI: 10.14309/01.ajg.0000702452.53969.ae.Peer-Reviewed Original Research